Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 9/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.44 |
| ▸ | RARB | P10826 | 3/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996598 | 0.80 | GRM2 (0.53) | GRM2PPARATP53TSHRPLA2G4B | |
| SCHEMBL8256435 | 0.76 | GRM2 (0.69) | GRM2PPARATP53TSHRPLA2G4B | |
| SCHEMBL2002750 | 0.76 | GRM2 (0.52) | GRM2PPARATP53TSHRPLA2G4B | |
| SCHEMBL1998937 | 0.75 | GRM2 (0.66) | GRM2PPARA | |
| SCHEMBL5533623 | 0.74 | GRM2 (0.53) | GRM2PPARATP53TSHRPLA2G4B | |
| SCHEMBL6244487 | 0.69 | GRM2 (1.00) | GRM2PPARA | |
| SCHEMBL10744397 | 0.67 | GRM2 (0.95) | GRM2PPARA | |
| SCHEMBL503727 | 0.66 | TP53 (0.96) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL736876 | 0.66 | TP53 (0.89) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL10798086 | 0.66 | TP53 (0.89) | TP53TSHRPLA2G4BRARBPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960417-B2 | Such as 1-(2,2-dimethylpropyl)-4-propyl-5-{4-[4-(1H-tetrazol-5-yl)phenoxy]butoxy}-1H-indole; neurological and psychiatric disorders | MERCK SHARP & DOHME CORP. (US) | 2011-06-14 | — | — | US | claimed |
| US-20080176904-A1 | Benzazole Potentiators of Metabotropic Glutatmate Receptors | MERCK SHARP & DOHME CORP. | 2008-07-24 | — | — | US | claimed |
| US-7960417-B2 | Such as 1-(2,2-dimethylpropyl)-4-propyl-5-{4-[4-(1H-tetrazol-5-yl)phenoxy]butoxy}-1H-indole; neurological and psychiatric disorders | MERCK SHARP & DOHME CORP. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20080176904-A1 | Benzazole Potentiators of Metabotropic Glutatmate Receptors | MERCK SHARP & DOHME CORP. | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176904-A1 | Benzazole Potentiators of Metabotropic Glutatmate Receptors | GRM2, GRM3, GRIK2 | GRM2 1/4885PPARA 222/4885TP53 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.